Background: Efavirenz is currently suggested as an alternative to recommended antiretroviral (ARV) regimens by the Department of Health and Human Services for the treatment of HIV-1 in ARVnaive patients. A mid-dosing interval therapeutic range between 1000 and 4000 ng/mL for efavirenz has been proposed in the literature, with patients more likely to experience virologic failure below this range and adverse effects above. The current study reports an analysis of virologic outcome between those above, below, or within the reported efavirenz therapeutic range (1000-4000 ng/mL) and within subgroups.
INTRODUCTION
Efavirenz is a nonnucleoside reverse transcriptase inhibitor (NNRTI) commonly prescribed with nucleos(t)ide reverse transcriptase inhibitors (NRTIs) for combination use in the HIV-1 patient population. The US Department of Health and Human Services Guidelines for the treatment of HIV-1 antiretroviral (ARV)-naive patients suggest efavirenz as an alternative third drug agent. 1 Globally, it is recommended as a preferred regimen combined with tenofovir disoproxil fumarate + lamivudine (or emtricitabine) when initiating ARV therapy, based on moderate-quality evidence that this regimen was less frequently associated with severe adverse events and had improved efficacy when it was systematically compared with other NNRTI and protease inhibitor regimens. 2 In a study by Marzolini et al, 3 efavirenz plasma concentrations were examined for the utility of prediction of HIV viral failure and central nervous system adverse events. They found that patients with low (,1000 ng/mL) and high (.4000 ng/mL) mid-interval (average 14 hours after intake) efavirenz concentrations were more likely to experience virologic failure and central nervous system adverse events, respectively. 3 When using population pharmacokinetic modeling, a possible relationship between viral load and average efavirenz concentrations was shown to exist. 4 Therapeutic drug monitoring may be beneficial for certain conditions, such as in pregnant women, those with organ dysfunction, and those at risk of drug interactions 5 to ensure that drug concentrations do not become subtherapeutic or reach toxic levels. The effect of genotypic differences on efavirenz concentrations, as well as the allele frequency of the major metabolizing enzyme in different race and ethnicity groups, has been described previously. [6] [7] [8] Population pharmacokinetic modeling has shown that weight and fat-free mass affect the clearance of efavirenz; however, the association of sex with concentration differences seems to be inconclusive. [8] [9] [10] AIDS Clinical Trials Group (ACTG) study A5202 was a study in HIV-1 treatment-naive participants investigating initial treatment options. [11] [12] [13] This study enrolled 1857 eligible participants and included the collection of drug concentration data in the majority, thus providing an opportunity to evaluate the therapeutic range used in the literature for efavirenz. We report on the comparison of participants who experienced virologic failure to those who did not in the efavirenz-containing arms of ACTG study A5202 and efavirenz concentrations between these groups. The objective of this analysis was to compare virologic failure between those above, below, or within the reported efavirenz therapeutic range (1000-4000 ng/mL) and within subgroups.
METHODS

Trial Study Design
Study A5202 was a phase IIIB randomized equivalence study to compare 4 ARV regimens in treatment-naive HIV-1-infected adults: atazanavir with ritonavir (300 mg/100 mg) or efavirenz (600 mg) and double-blinded, placebo-controlled NRTI backbone of abacavir/lamivudine (600 mg/300 mg) or tenofovir disoproxil fumarate/emtricitabine (300 mg/200 mg). Randomization was stratified by participants' HIV-1 RNA level (,100,000 or $100,000 copies/mL) at screening, and participants were randomized 1:1:1:1 to 1 of the 4 treatment arms. The primary efficacy outcome was time from randomization to virologic failure, defined as a confirmed plasma HIV-1 RNA level $1000 copies/mL at or after 16 weeks and before 24 weeks or $200 copies/mL at or after 24 weeks after randomization. 11 Results from the primary and main secondary analyses have been previously published. [11] [12] [13] Drug Concentration and HIV-1 RNA Sampling
In study A5202, participants who received efavirenz in the evening were scheduled for 2 visits within the first 24 weeks of therapy to obtain 3 blood samples for drug concentrations-visits A and B. Visit A was to be scheduled around the observed dosing of the NRTI backbone. For 4 days before the visit, participants were asked to switch their NRTI dosing to the morning (but not their efavirenz dose because of toxicity concerns), and on the fifth day, 2 samples were to be obtained (;4 hours apart) around the dosing of the NRTI backbone. Visit B was planned to consist of an efavirenz plasma sample 5-15 hours after an efavirenz dose. Visit A could occur before or after visit B. A total of 3 efavirenz plasma samples were to be drawn within the first 24 weeks of therapy. The measurement of HIV-1 RNA was evaluated before study entry, at study entry, weeks 4, 16, 24, then every 12 weeks, at final study evaluation, evaluation after virologic failure was confirmed, and if there was a premature discontinuation of study treatment. Medication adherence training was provided at study entry. Self-reported adherence questionnaires were administered at weeks 8 and 24.
Efavirenz plasma concentrations were quantified by 2 ACTG-supported pharmacology laboratories utilizing validated high-performance liquid chromatography assays. 14 The methods used to quantitate efavirenz used reversed-phase high-performance liquid chromatography (RP-HPLC) using a photodiode array detector scanning at 248 nm. The methods had a lower limit of quantitation of 0.1 mcg/mL with an interday imprecision ranging from 3.6% to 5.4% (coefficients of variance, CV%) as determined based on the quality control samples. The laboratories participated in twice-annual proficiency testing to assure that the efavirenz results derived from the laboratories' methods remained accurate. 15 HIV-1 RNA measurement was performed for screening at any laboratory certified under the Clinical Laboratory Improvement Amendments and after screening at Johns Hopkins University.
Statistical Analysis
This study examined efavirenz concentrations from subjects enrolled in A5202, drawn between 14 and 190 days after initiating efavirenz. Subjects were further separated to investigate those who had "high" (at least 1 plasma concentration .4000 ng/mL), "within" (all plasma concentrations within the range of 1000-4000 ng/mL), "low" (at least 1 plasma concentration ,1000 ng/mL), and "both" (at least 1 sample ,1000 ng/mL and 1 sample .4000 ng/mL) plasma concentrations. Subjects were included in the analysis if they were taking efavirenz for at least 14 days before sampling, to ensure samples were collected at steady state. 16 In addition, efavirenz concentrations were used if the sample was drawn beyond 6.0 hours after efavirenz administration to ensure that concentrations were collected beyond the absorption phase. 16 Five samples were not included in the analysis because they had either unknown storage conditions or were drawn outside the limits of the protocol. In addition, 1 sample (67 ng/mL) that was below the limit of quantification (100 ng/mL), but not 0 ng/mL, was removed from analysis; however, this did not change the efavirenz concentration group for this participant.
A5202 had a primary efficacy end point that considered time to virologic failure. In the present exploratory analysis, a binary outcome was used (virologic failure-Yes/No). Associations between virologic failure and covariates were tested using Fisher's exact test for categorical or the Wilcoxon ranksum test for continuous covariates. The multivariable relationship between virologic failure and covariates was statistically assessed using logistic regression. Covariates included race/ ethnicity, history of intravenous (IV) drug use, sex, NRTI backbone, age at study entry, screening HIV-1 RNA stratification level, first available weight measured during drug plasma sampling, and efavirenz plasma concentration group ("high," "low," "within," and "both"). Furthermore, the interactions between the concentration grouping variable with race/ethnicity and first available weight during efavirenz sampling (categorized by quartile) and between race/ethnicity and sex were considered. Model fitting was implemented with R. 17 Wald tests were performed to assess statistical significance. 18 All tests were 2 sided and tested at a 0.05 nominal significance level.
Three covariates (race/ethnicity, history of IV drug use, and efavirenz concentration group) had participant groups that consisted of a small number of participants. To address the computational problems, this introduces when fitting the logistic regression, categories were combined as follows: race/ethnicity-Asian (n = 11), American Indian and Alaskan (n = 8), and .1 race (n = 5) were combined as "Other. Moreover," history of IV drug use "Currently" (n = 2) and "Previously" (n = 72) were combined, as well as efavirenz plasma concentration groups: "low" (n = 106) and "both" (n = 8) were combined because the present analysis was focused on the association of efavirenz concentrations and virologic failure rather than toxicity.
RESULTS
A total of 929 study participants were randomized into the 2 efavirenz treatment arms, and 86% (n = 802) of these participants contributed a total of 2154 efavirenz drug concentration samples. Among these participants, 2000 efavirenz samples from 796 study participants met initial inclusion criteria for univariate analysis, and 784 participants contributed 1895 samples for the multivariable analysis (Fig. 1) . Figure 2 shows efavirenz concentrations for participants included in the current analysis, and these samples were collected within 14-190 days of beginning efavirenz. Most efavirenz samples were collected 10-15 hours postdose in A5202.
Participant characteristics by virologic failure status are contained in Table 1 . In univariate analyses, statistically significant differences were found when comparing the efavirenz concentration groups [22 failures among the "low" concentration group (19%), 65 failures among the "within" concentration group (12%), and 11 failures among the "high" concentration group (9%)], when evaluating virologic failure as an outcome (P = 0.04). In addition, the proportion of participants with virologic failure differed across race/ethnicity groups (P = 0.03) with black non-Hispanic participants observed to have the highest (17%). Last, there was a significant difference in the age distribution at study entry between those with virologic failure versus no failure (P = 0.01), as those who experienced virologic failure were slightly younger. All other subgroup comparisons showed nonsignificant differences when evaluating the outcome of virologic failure.
In the multivariable logistic regression analysis, the covariates race/ethnicity (with "other," white non-Hispanic, Hispanic, and black non-Hispanic being associated with an increasing probability of failure, with the white non-Hispanic population used as reference) and age (with increased age being associated with a decreasing probability of failure) were found to be statistically significant. Table 2 contains the corresponding odds ratios for covariates assessed in the logistic regression. The association of efavirenz plasma concentration groups with virologic failure depends on weight with the risk of virologic failure in the "low" group compared with the "within" or "high" efavirenz concentration groups being higher at lower weight (P = 0.036). Given that weight was treated as numeric in the multivariate analysis, Figure 3 displays the estimated odds ratios for group comparisons at the quartiles of the observed weight distribution, specifically at values 68, 76, and 87.7 kg.
DISCUSSION
This secondary analysis of A5202 clinical trial data found that the association of efavirenz plasma concentrations with virologic failure depends on weight. A small number of subjects had measured efavirenz concentrations that fell into both the "high" and "low" categories. For the necessity of the analysis, and based on the main objective of the study, this group was combined with those in the "low" group. The probability of virologic failure increased from the "high," to the "within," and then "low" efavirenz concentration groups. Although this suggests "high" levels were advantageous, this would need to be balanced against the potential for adverse effects, and this analysis did not look at the potential toxicity associated with high levels.
In the multivariable logistic regression, race/ethnicity, age at baseline, and the interaction term between efavirenz concentration group and weight were significantly associated with virologic failure. Sex was not significantly associated with virologic failure, which was primarily in agreement with a study of time to virologic failure in the A5202 study by Smith et al. 19 In addition, there was no significant difference in outcome when evaluating history of IV drug use, the assigned NRTI backbone, and HIV-1 RNA stratification level at screening.
The association of efavirenz plasma concentration groups with virologic failure depends on weight, with the risk of virologic failure in the "low" group compared with the "within" or "high" efavirenz concentration groups being higher at lower weight. In a study by Marzolini et al 20 examining time to initial undetectable viral load in treatment-naive subjects on efavirenz, underweight subjects were significantly less likely to obtain an undetectable viral load when compared with their normal-weight counterparts; however, this was not observed between heavier and normal-weight participants. In addition, the underweight group compared with normal weight had a significantly higher cumulative probability of virological rebound. 20 One hypothesis that may explain the findings seen in the current study is that those patients who were underweight were more likely to have toxicity associated with poorer adherence. To our knowledge, this relationship has not been examined in the literature. However, multivariate analysis (n = 41) indicated that efavirenz concentrations show a significant (P = 0.015) inverse relationship with body weight. 21 Younger age at study entry was associated with an increased probability of virologic failure, the average (range) was 36 and 39 , between those experiencing virologic failure and those not. Others have reported younger age as an independent predictor of virologic failure in HIVinfected patients on NNRTI-based regimens. 22 Although in our population there was only a 3-year mean difference between those with virologic failure and nonfailure, there was a significant shift in the distribution. A difference was also observed when comparing virologic failure and nonfailure among race/ethnicity groups. The probability of virologic failure in the current analysis was greatest for black nonHispanic participants. This was also shown in a separate analysis that included A5202 data for subjects who had confirmed virologic failure and pretreatment and failure gene sequence results (265/269), in which the most common race/ethnicity was those who were black non-Hispanic. 23 In the current study, within the virologic failure group, 26% of white nonHispanic subjects experienced at least 1 concentration out of the therapeutic range, with black non-Hispanic subjects experiencing 43% (20/47) . Among the black non-Hispanic subjects with an out-of-range efavirenz concentration, 40% (n = 8) had at least 1 concentration above the therapeutic range and 55% (n = 11) with at least 1 below the range, with 5% (n = 1) experiencing both above and below. Compared with white non-Hispanic, those who were black non-Hispanic have been associated with an increased risk of virologic failure in adjusted analyses. 24 Furthermore, a greater impact of nonadherence on virologic failure has been reported for black versus white subjects on an efavirenz-containing regimen for the initial treatment of HIV infection. 25 In a genome-wide association study, involving multiple ACTG studies, including A5202, 3 CYP2B6 polymorphisms were found to be independently associated with efavirenz C min (minimum plasma concentration). 7 However, predictive genetic variants of efavirenz exposure were examined in a study that included A5202 data for those related to the lowest efavirenz plasma exposure and none were found to have a significant association with virologic failure. 26 In addition, the study found no genome-wide significant associations with virologic response for efavirenz. 26 A therapeutic range for efavirenz between 1000 and 4000 ng/mL for mid-dosing interval samples has been used previously. 27, 28 However, studies such as ENCORE1, which compared the efficacy of 400 mg of efavirenz with the standard dose of 600 mg at 48 and 96 weeks in treatment-naive patients, suggest that 1000 ng/mL does not necessarily represent the optimal efficacy concentration cutoff based on the proportion of subjects with both a plasma viral load level $200 copies/mL and predicted efavirenz mid-dosing concentrations ,1000 ng/mL compared with .1000 ng/mL (P = 0.059). 29, 30 However, caution is recommended in interpretation based on the limited number of virologic failures and projection of pharmacokinetic parameters to a pharmacodynamic outcome at a much later time point. 30 In addition, a range of possible minimum effective concentrations were suggested (470-760 ng/mL), but additional analysis would be required to confirm this. 30 Other studies have reported no correlation between viral suppression and efavirenz exposure. 31 In a study comparing the efficacy of 3-times-a-week dosing to daily dosing of the combined ARV medication efavirenz, emtricitabine, and tenofovir disoproxil fumarate in HIV-1 patients, with no history of virologic failure or resistance mutations to study drugs, all subjects (in both arms) maintained HIV-1 RNA ,37 copies/mL for 24 weeks. In this study, the 3-day-per-week group had significantly lower efavirenz concentrations (plasma concentrations were measured 12 hours after the dose in the daily treatment arm and 60 hours after the dose in the 3-times-a-week arm). 32 Overall, this study found that in addition to plasma concentrations and weight, race/ethnicity, and age at study entry may be significantly associated with virologic failure. In addition, the association of efavirenz plasma concentration groups with virologic failure depends on weight with the risk of virologic failure in the "low" group compared with the "within" or "high" efavirenz concentration groups being increased at lower weight.
Limitations to the current study include unknown reasons for subtherapeutic levels, such as possible drug-drug interactions, nonadherence, comorbid conditions, or other unmeasured confounding factors. Although a mean intrapatient variability of about 30% (CV%) on repeated efavirenz plasma concentration measurements over approximately 3-month intervals has been reported, 3, 33 the current study assumes that an efavirenz concentration drawn within 6 months of beginning therapy may affect an outcome at a time point later than sampling, as the original study was continued for a duration lasting 96 weeks after the enrollment of the last participant. As the current analysis evaluated sparse plasma samples collected within the first 190 days of therapy, the potential limitation of unknown adherence is recognized, as adherence can vary widely over time and across a population. In addition, we did not evaluate the opposite end of the recommended therapeutic range of efavirenz (.4000 ng/mL), which is associated with increased risk of toxicity, which could possibly lead to decreased adherence and may ultimately result in virologic failure.
CONCLUSIONS
As decreased efavirenz dosing is further examined for use on a global basis to decrease cost and adverse effects while maintaining efficacy, additional analysis is recommended to determine the most appropriate concentration value to define the lower limit of the efavirenz therapeutic range in varied populations. This future direction could help determine the absolute cutoff associated with efficacy, to aid in improving the outcome of ART around the globe.
